Advanced searches left 3/3
Search only database of 8 mil and more summaries

Merck & Co

Summarized by PlexPage
Last Updated: 20 November 2021

* If you want to update the article please login/register

General | Latest Info

Merck & Co

TypePublic company
Traded asNYSE : MRK, DJIA component, S&P 100 component, S&P 500 component
IndustryPharmaceutical industry
Founded1891 ; 130 years ago ( 1891 ) as a subsidiary of Merck (founded 1668) 1917 as an independent company
FoundersTheodore Weicker George Merck
HeadquartersKenilworth, New Jersey , U.S.
Area servedWorldwide
Key peopleKenneth C. Frazier (Executive Chairman) Robert M. Davis (President and CEO)
RevenueUS$ 47.994 billion (2020)
Operating incomeUS$8.791 billion (2020)
Net incomeUS$7.067 billion (2020)
Total assetsUS$89.800 billion (2020)
Total equityUS$29.270 billion (2020)
Number of employees74,000 (2020)
Websitemerck.com (valid only in U.S. and Canada), msd.com (valid internationally)

Merck & Co. , Inc. Is an international healthcare firm. Merck is among the biggest pharmaceutical firms on the planet. People who state the firm's products injured them have filed countless suits against Merck. The Big Pharma business has also faced license legal actions and criminal charges for unlawful advertising and price gouging. Merck remains to create new medicines for cancer cells and diabetic issues. The medication maker also has some new vaccines in the works, including one for Ebola.

Outside the United States and Canada, Merck is referred to as Merck Sharp & Dohme.

Friedrich Jacob Merck opened up the pharmaceutical company under the name Angel Pharmacy. Heinrich Emanuel Merck transformed the course of the business under its new name E. Merck. The painkiller was on the marketplace for five years before Merck disengaged. Merck refuted reports of unsafe heart side effects for years. The Company markets these human health and wellness pharmaceutical products mainly to drug dealers and sellers, medical facilities, federal government companies and handled healthcare service providers such as health care companies.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Merck & Co (latest news)

Merck paused development of MK-8507 after seeing reductions in white blood cells in HIV patients who took the non-nucleoside reverse transcriptase inhibitor in combination with foundation therapy islatravir in a stage 2 scientific test. Merck's plan was to make use of MK-8507 to take islatravir past the once-daily setting allowed by its combination with doravirine, therefore establishing the company as a player as the HIV market relocates to much more practical regimens. The troubles with MK-8507 have led Merck to uncover evidence that islatravir may influence white blood cell counts to some degree. The testimonial disclosed a dose-dependent decrease in leukocyte matters in a recurring stage 2 trial that is evaluating a month-to-month islatravir formulation for PrEP.

The obstacle may mean that Gilead has to go back to the drawing board to establish new long-acting alcoholic drinks as the marketplace possibility for the partnered combo diminishes, RBC said.

The FDA has approved Keytruda for treating patients with early kidney cell carcinoma-the most typical sort of kidney cancer-at intermediate-high or high danger of recurrence after surgical procedure, Merck stated Thursday.

For adjuvant kidney cancer, Keytruda can soon entertain from Roche's Tecentriq; the stage 3 IMmotion010 test of the PD-L1 prevention births a main completion day in January 2022. Last month, Tecentriq came to be the first in the PD-1/ L1 class to go into post-surgery non-small cell lung cancer with an FDA authorization in stage II to IIIA, PD-L1-positive patients. Besides, doctors appear undecided over the idea of adjuvant PD-1/ L1 treatment for lung cancer as they await readouts from various other medicines and more mature information on client survival. Merck has an expansive HIV medical development program reviewing islatravir across a range of dosing routines, for both the treatment of HIV-1 in combination with various other antiretroviral agents and for the avoidance of HIV-1 as a monotherapy. Merck recently revealed positive topline outcomes from the ILLUMINATE SWITCH A and ILLUMINATE SWITCH B Phase 3 clinical trials. Extreme intense exacerbations of HBV have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products consisting of lamivudine or tenofovir disoproxil fumarate, which are parts of DELSTRIGO. Situations of intense renal failure after initiation of several or high-dose NSAIDs have been reported in patients with risk variables for kidney dysfunction that appeared stable on TDF.

If DELSTRIGO is co-administered with rifabutin, take one tablet of DELSTRIGO once daily, adhered to by one tablet computer of doravirine approximately 12 hours after the dosage of DELSTRIGO.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.